Celso Chavez
Family Medicine · Lewiston, IDNPI 1386795565
Payments from drug & device makers
Across 81 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$245
- GSK$228
- Teva Pharmaceuticals USA, Inc.$118
- Amgen$102
- Pfizer$96
- Sanofi-aventis U.S. LLC$92
- plus $640 from 19 others
What the payments were for
- Food & beverage$1,41293%
- Education$1097%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $245 |
| GSK | 13 | $228 |
| Teva Pharmaceuticals USA, Inc. | 3 | $118 |
| Amgen | 5 | $102 |
| Pfizer | 7 | $96 |
| Sanofi-aventis U.S. LLC | 3 | $92 |
| Astellas Pharma US Inc | 2 | $87 |
| Bayer | 3 | $61 |
| Lilly USA, LLC | 4 | $59 |
| Novo Nordisk | 2 | $58 |
| Mylan Specialty L.p. | 3 | $50 |
| Johnson & Johnson | 4 | $38 |
| Abbott | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Electromed, Inc. | 1 | $32 |
| Merck | 2 | $29 |
| Exact Sciences | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Gilead | 1 | $12 |
| Phadia US Inc. | 1 | $11 |
| Therapeuticsmd, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$100
- AJOVY$100
How this compares
$1,521 in reported general payments places this provider in the 80th percentile of 803 family medicine providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $8,456 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,758 |
| Levothyroxine Sodium | 97 | $1,074 |
| Sumatriptan Succinate | 15 | $850 |
| Lidocaine | 12 | $810 |
| Potassium Chloride | 40 | $765 |
| Omeprazole | 91 | $551 |
| Metoprolol Succinate | 37 | $547 |
| Trazodone Hcl | 29 | $511 |
| Gabapentin | 35 | $493 |
| Losartan Potassium | 59 | $419 |
| Allopurinol | 35 | $380 |
| Simvastatin | 36 | $361 |
| Pantoprazole Sodium | 32 | $360 |
| Tamsulosin Hcl | 39 | $333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $96 | $8,45611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 803 family medicine providers in Idaho.
Other family medicine in Lewiston
- Mark TurnerMeridian$40.5M
- David ButukMeridian$15.2M
- Gary SoucieBlackfoot$5.8M
- Brock McConneheyBoise$4.5M
- William LaitinenMiddleton$1.1M
- Diane McConneheyBoise$681K
- Flint PackerIdaho Falls$587K
- Paul BeckettBlackfoot$344K
- Elaine DavidsonMeridian$303K
- Kenneth CongerSandpoint$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.